PrimeVigilance Enhances Efficiency and Patient Safety with Oracle Argus Platform
PrimeVigilance, a Contract Research Organization (CRO), has implemented Oracle's (NYSE:ORCL) Argus platform to enhance its pharmacovigilance services. The AI-powered platform, which processes 10 million adverse event cases annually, will help optimize drug development programs and improve patient safety monitoring.
Additionally, PrimeVigilance has joined Oracle's Lighthouse development program as a collaborator, aiming to accelerate pharmacovigilance excellence across the life sciences industry. The partnership focuses on improving operational efficiency, data management, regulatory compliance, and patient safety insights through cloud-based, AI-enabled solutions.
PrimeVigilance, un'organizzazione di ricerca a contratto (CRO), ha adottato la piattaforma Argus di Oracle (NYSE:ORCL) per potenziare i suoi servizi di farmacovigilanza. La piattaforma basata sull'intelligenza artificiale, che gestisce 10 milioni di casi di eventi avversi ogni anno, contribuirà a ottimizzare i programmi di sviluppo dei farmaci e a migliorare il monitoraggio della sicurezza dei pazienti.
Inoltre, PrimeVigilance è entrata a far parte del programma di sviluppo Lighthouse di Oracle come collaboratore, con l'obiettivo di accelerare l'eccellenza nella farmacovigilanza nel settore delle scienze della vita. La partnership si concentra sul miglioramento dell'efficienza operativa, della gestione dei dati, della conformità normativa e delle informazioni sulla sicurezza dei pazienti tramite soluzioni cloud basate su intelligenza artificiale.
PrimeVigilance, una Organización de Investigación por Contrato (CRO), ha implementado la plataforma Argus de Oracle (NYSE:ORCL) para mejorar sus servicios de farmacovigilancia. La plataforma impulsada por inteligencia artificial, que procesa 10 millones de casos de eventos adversos anualmente, ayudará a optimizar los programas de desarrollo de medicamentos y a mejorar la monitorización de la seguridad de los pacientes.
Además, PrimeVigilance se ha unido al programa de desarrollo Lighthouse de Oracle como colaborador, con el objetivo de acelerar la excelencia en farmacovigilancia en la industria de las ciencias de la vida. La colaboración se centra en mejorar la eficiencia operativa, la gestión de datos, el cumplimiento normativo y los conocimientos sobre seguridad del paciente mediante soluciones en la nube habilitadas con IA.
PrimeVigilance는 계약 연구 기관(CRO)으로서 Oracle(NYSE:ORCL)의 Argus 플랫폼을 도입하여 약물 안전성 감시 서비스를 강화했습니다. 연간 1,000만 건의 이상 반응 사례를 처리하는 AI 기반 플랫폼은 의약품 개발 프로그램을 최적화하고 환자 안전 모니터링을 개선하는 데 기여할 것입니다.
또한 PrimeVigilance는 Oracle의 Lighthouse 개발 프로그램에 협력사로 참여하여 생명과학 산업 전반에 걸쳐 약물 안전성 감시의 우수성을 가속화하는 것을 목표로 하고 있습니다. 이 파트너십은 클라우드 기반 AI 솔루션을 통해 운영 효율성, 데이터 관리, 규제 준수 및 환자 안전 인사이트 개선에 중점을 둡니다.
PrimeVigilance, une organisation de recherche sous contrat (CRO), a mis en œuvre la plateforme Argus d'Oracle (NYSE:ORCL) pour renforcer ses services de pharmacovigilance. Cette plateforme alimentée par l'IA, qui traite 10 millions de cas d'effets indésirables chaque année, contribuera à optimiser les programmes de développement de médicaments et à améliorer la surveillance de la sécurité des patients.
De plus, PrimeVigilance a rejoint le programme de développement Lighthouse d'Oracle en tant que collaborateur, visant à accélérer l'excellence en pharmacovigilance dans l'industrie des sciences de la vie. Ce partenariat se concentre sur l'amélioration de l'efficacité opérationnelle, la gestion des données, la conformité réglementaire et les informations sur la sécurité des patients grâce à des solutions cloud dotées d'intelligence artificielle.
PrimeVigilance, ein Contract Research Organization (CRO), hat die Argus-Plattform von Oracle (NYSE:ORCL) implementiert, um seine Pharmakovigilanz-Dienstleistungen zu verbessern. Die KI-gestützte Plattform, die jährlich 10 Millionen Fälle von unerwünschten Ereignissen verarbeitet, wird dazu beitragen, Arzneimittelentwicklungsprogramme zu optimieren und die Überwachung der Patientensicherheit zu verbessern.
Darüber hinaus ist PrimeVigilance dem Lighthouse-Entwicklungsprogramm von Oracle als Partner beigetreten, mit dem Ziel, Exzellenz in der Pharmakovigilanz in der gesamten Life-Sciences-Branche zu beschleunigen. Die Partnerschaft konzentriert sich auf die Verbesserung der Betriebseffizienz, Datenverwaltung, regulatorischen Compliance und Patientensicherheits-Insights durch cloudbasierte, KI-gestützte Lösungen.
- Integration of AI-powered Oracle Argus platform enhances safety monitoring capabilities
- Access to industry-leading platform processing 10 million adverse event cases annually
- Strategic collaboration through Oracle Lighthouse development program
- None.
Insights
Oracle's Argus platform adoption by PrimeVigilance strengthens Oracle's position in the lucrative pharmacovigilance market with minimal immediate revenue impact.
This partnership announcement between Oracle and PrimeVigilance represents a strategic win for Oracle in the competitive healthcare technology space, though with limited immediate financial impact. The selection of Oracle Argus by PrimeVigilance, part of the Ergomed Group, reinforces Oracle's market position in the growing pharmacovigilance sector.
The announcement highlights that Oracle Argus already processes 10 million adverse event cases annually, demonstrating its established market presence. Oracle's designation of PrimeVigilance as a "Lighthouse development program collaborator" indicates this is more than a standard client acquisition – it's a co-development relationship that could yield product improvements valuable to other pharmaceutical customers.
What's particularly notable is the emphasis on AI-powered capabilities in the platform. This aligns with the broader industry trend toward automation of safety data processing, where AI can potentially reduce manual review time while improving accuracy. For Oracle, this showcases their AI integration strategy within their health sciences portfolio.
The timing is opportune as regulatory requirements for safety monitoring continue to increase globally, creating demand for more sophisticated pharmacovigilance solutions. Oracle's positioning of Argus as the "gold standard" reflects their attempt to maintain premium pricing in this specialized market segment against competing solutions.
While this single contract won't materially impact Oracle's
Contract Research Organization aims to improve data management, accuracy, and safety with Oracle's AI-powered pharmacovigilance platform
"Changing regulations and the rapid increase of data from new sources demand improved safety strategies," said Sally Amanuel, president, PrimeVigilance. "Using the AI-powered Oracle Argus platform, we can enhance safety monitoring, drive efficiency, and empower our teams to focus on value-added activities that can help to improve patient outcomes for our clients."
Oracle Argus is a leading pharmacovigilance safety platform that handles 10 million adverse event cases each year, providing the benchmark platform for processing, analyzing, and reporting safety data at scale for clinical trials.
Accelerating safety
PrimeVigilance also recently became an Oracle Lighthouse development program collaborator for Argus. PrimeVigilance will bring its CRO perspective to this innovation program with goals of further accelerating pharmacovigilance excellence across the life sciences industry to increase operational efficiency, optimize data management and regulatory compliance, and enhance patient safety insights.
"Oracle Argus has been the gold standard in pharmacovigilance for decades," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "Working with organizations like PrimeVigilance we are building on that excellence to deliver cloud-based, AI-enabled solutions that improve safety monitoring for the benefit of the industry and the patients waiting for potentially lifesaving solutions."
About PrimeVigilance
PrimeVigilance, an Ergomed Group Limited company, is the leading pharmacovigilance specialist provider delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from operational hubs based in
Our flexible, customized approach allows us to deliver services that align with client clinical and post-marketing needs. We provide pharmacovigilance solutions to 200+ clients who distribute their products worldwide and manage a comprehensive global pharmacovigilance system. For more information, visit www.primevigilance.com or contact info@primevigilance.com.
About Oracle Life Sciences
Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. With more than 20 years of experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements—empowering the Life Sciences industry to improve patient outcomes. Learn more at www.oracle.com/lifesciences.
About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at oracle.com.
Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.
View original content to download multimedia:https://www.prnewswire.com/news-releases/primevigilance-enhances-efficiency-and-patient-safety-with-oracle-argus-platform-302497968.html
SOURCE Oracle
FAQ
What is the purpose of PrimeVigilance implementing Oracle Argus platform?
How many adverse event cases does Oracle Argus handle annually?
What is PrimeVigilance's role in Oracle's Lighthouse development program?
How will Oracle Argus help address changing regulations in pharmacovigilance?
